RETATRUTIDE

Retatrutide, also known as LY3437943, is a peptide that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon. It is studied for its effects on body-weight regulation, glucose control and broader metabolic function.

Studied Uses
Retatrutide has been investigated in clinical studies involving:

Obesity and overweight
Body-weight and body-composition changes
Type 2 diabetes and glycaemic control
Metabolic dysfunction-associated liver fat
Cardiovascular and obesity-related health outcomes
Phase 2 trials examined retatrutide in adults with obesity or overweight and in people with type 2 diabetes. Additional studies have investigated its effects on liver fat, while Phase 3 trials continue to evaluate its efficacy and safety across obesity and related metabolic conditions.

How It Works
Retatrutide acts as a single-molecule agonist at the GIP, GLP-1 and glucagon receptors.

GIP and GLP-1 receptor activation influences glucose-dependent insulin signalling, appetite regulation and food intake. Glucagon-receptor activation affects hepatic metabolism and energy expenditure. Researchers are studying whether the combined activity of all three pathways can produce complementary effects on glucose regulation, appetite, energy balance and body weight.

Product Details
Product: Retatrutide
Strength: 10 mg
Form: Lyophilized powder
Presentation: Single vial